ATE407698T1 - Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung - Google Patents

Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung

Info

Publication number
ATE407698T1
ATE407698T1 AT04750581T AT04750581T ATE407698T1 AT E407698 T1 ATE407698 T1 AT E407698T1 AT 04750581 T AT04750581 T AT 04750581T AT 04750581 T AT04750581 T AT 04750581T AT E407698 T1 ATE407698 T1 AT E407698T1
Authority
AT
Austria
Prior art keywords
compositions
methods
inflammatory bowel
bowel disease
treating inflammatory
Prior art date
Application number
AT04750581T
Other languages
English (en)
Inventor
Lesley Pickford
Christopher Bebbington
Geoffrey Yarranton
David King
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of ATE407698T1 publication Critical patent/ATE407698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04750581T 2003-04-23 2004-04-23 Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung ATE407698T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46515503P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
ATE407698T1 true ATE407698T1 (de) 2008-09-15

Family

ID=33311000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04750581T ATE407698T1 (de) 2003-04-23 2004-04-23 Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung

Country Status (21)

Country Link
US (2) US7939076B2 (de)
EP (1) EP1631312B1 (de)
JP (1) JP4628357B2 (de)
KR (1) KR100817351B1 (de)
CN (2) CN100409897C (de)
AT (1) ATE407698T1 (de)
AU (1) AU2004232362C1 (de)
BR (1) BRPI0410495A (de)
CA (2) CA2522957C (de)
DE (1) DE602004016499D1 (de)
DK (1) DK1631312T3 (de)
ES (1) ES2313039T3 (de)
IL (1) IL171356A (de)
MX (1) MXPA05011409A (de)
NZ (1) NZ542866A (de)
PL (1) PL1631312T3 (de)
PT (1) PT1631312E (de)
SG (1) SG173919A1 (de)
SI (1) SI1631312T1 (de)
WO (1) WO2004093908A2 (de)
ZA (1) ZA200508390B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542988A (en) * 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
CA2522957C (en) 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
KR101166901B1 (ko) 2010-04-16 2012-07-19 송영완 임플란트용 주입기
US20130209476A1 (en) * 2010-06-04 2013-08-15 The Brigham And Women's Hospital Inc. Treatment of inflammatory disorders
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
EP2951283A4 (de) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Zusammensetzungen und verfahren
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
CA2957966C (en) * 2014-08-14 2021-11-30 Brown University Compositions for stabilizing and delivering proteins
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
CN107074943B (zh) 2016-07-14 2018-08-24 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
US12514897B2 (en) * 2017-06-02 2026-01-06 Goodgut S.L. Grape skin for use in the treatment of dysbiosis
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
CN112056275B (zh) * 2020-09-27 2022-05-10 澎立生物医药技术（上海）有限公司 一种肠粘膜炎动物模型及其构建方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5516515A (en) 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
IL88377A (en) 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
FR2653445B1 (fr) 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
JPH06510061A (ja) 1991-08-30 1994-11-10 ジェネンテク，インコーポレイテッド Ｉｄｄｍの治療法
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
CA2148907C (en) 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AU7782894A (en) * 1993-09-17 1995-04-03 Laboratoire Europeen De Biotechnologie S.A. Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
AU1289595A (en) 1993-11-15 1995-06-06 Cell Therapeutics, Inc. Method for selectively inhibiting il-2 signal transduction
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
EP0983303B1 (de) 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
WO1999039211A1 (en) 1998-01-30 1999-08-05 Sampson Hugh A Prognostic allergy or inflammation test
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP4156324B2 (ja) 2002-09-30 2008-09-24 ローム株式会社 直流−交流変換装置、及び交流電力供給方法
CA2522957C (en) 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
NZ542988A (en) * 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
PT2418220T (pt) * 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos

Also Published As

Publication number Publication date
ES2313039T3 (es) 2009-03-01
CN101318019A (zh) 2008-12-10
PT1631312E (pt) 2008-12-22
WO2004093908A3 (en) 2005-06-02
CA2522957C (en) 2013-10-22
CN100409897C (zh) 2008-08-13
JP2006524703A (ja) 2006-11-02
CA2522957A1 (en) 2004-11-04
CA2823468A1 (en) 2004-11-04
HK1082200A1 (en) 2006-06-02
US20110165158A1 (en) 2011-07-07
WO2004093908A2 (en) 2004-11-04
SI1631312T1 (sl) 2009-02-28
BRPI0410495A (pt) 2006-06-13
AU2004232362B2 (en) 2007-09-06
JP4628357B2 (ja) 2011-02-09
DE602004016499D1 (de) 2008-10-23
US7939076B2 (en) 2011-05-10
PL1631312T3 (pl) 2009-02-27
AU2004232362A1 (en) 2004-11-04
KR100817351B1 (ko) 2008-03-26
US8828393B2 (en) 2014-09-09
NZ542866A (en) 2009-07-31
EP1631312A2 (de) 2006-03-08
US20050152901A1 (en) 2005-07-14
SG173919A1 (en) 2011-09-29
CN1777444A (zh) 2006-05-24
AU2004232362C1 (en) 2008-05-29
ZA200508390B (en) 2006-06-28
EP1631312B1 (de) 2008-09-10
DK1631312T3 (da) 2009-01-19
KR20060015531A (ko) 2006-02-17
MXPA05011409A (es) 2005-12-12
CN101318019B (zh) 2012-08-29
IL171356A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
DE60142614D1 (de) Inität
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
MX2007000023A (es) Anticuerpos del receptor uno de interferon alfa, y sus usos.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
EA200802167A1 (ru) Лекарства и применения
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE402958T1 (de) Antagonisten des ige-rezeptors
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1631312

Country of ref document: EP